Ozanimod, under development to treat relapsing-remitting multiple sclerosis (RRMS), has greater efficacy on the annualized relapse rate (ARR) than most other first-line disease-modifying therapies (DMTs), according to 2 abstracts presented at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Ozanimod, an oral, sphingosine 1-phosphate (S1P) receptor modulator under development to treat relapsing-remitting multiple sclerosis (RRMS), has greater efficacy on the annualized relapse rate (ARR) than most other first-line disease-modifying therapies (DMTs), according to 2 abstracts presented at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
In one abstract, the researchers assessed the relative efficacy in relapses and safety of the treatment compared with other DMTs available to treat RRMS.1 The authors reviewed 44 trials that included 29,568 patients with RRMS. They found that ozanimod 1.0 mg was more effective at reducing ARR than glatiramer acetate 20 mg and 40 mg; interferon β-1a 30 mcg, 22 mcg, 44 mcg, and 250 mcg; and teriflunomide 7 mg and 14 mg. Ozanimod was comparable to cladribine 3.5 mg/kg, dimethyl fumarate 240 mg, fingolimod 0.5 mg, and peg-interferon β-1a 125 mcg.
The occurrence of serious adverse events (AEs) was comparable among all treatments and ozanimod had fewer AEs occur compared with alemtuzumab 12 mg, cladribine 3.5 mg/kg, dimethyl fumarate 240 mg, glatiramer acetate 40 mg, and peg-interferon β-1a 125 mcg.
According to the authors the efficacy and safety profile supports the development of oral ozanimod to treat RRMS.
In the second abstract, the authors used a number-needed-to-treat (NNT) analysis and a risk-benefit (RB) assessment to evaluate treatment effects of ozanimod compared with other first-line DMTs. They analyzed comparative risks and benefits from clinical trials of dimethyl fumarate 240 mg, fingolimod 0.5 mg, glatiramer acetate 20 mg and 40 mg, interferon β-1a 30 mcg and 44 mcg, ozanimod 1 mg, and teriflunomide 14 mg. ARR was calculated as NNTs relative to placebo.
For ozanimod and fingolimod has the lowest NNT (4) to prevent 1 relapse during 1 year relative to placebo, followed by dimethyl fumarate 240 mg (5), glatiramer acetate 20 mg and 40 mg and interferon β-1a 44 mcg (6), teriflunomide 14 mg (7), and lastly, interferon β-1a 30 mcg.
Ozanimod had a high incremental net benefit for ARR versus AEs relative to placebo and other DMTs.
References
1. Tencer T, Snedecor SJ, Nicoloso. Systematic literature review and network meta-analysis of ozanimod compared with other treatments in relapsing-remitting multiple sclerosis. Presented at: ECTRIMS 2019, Stockholm, Sweden; September 11-13, 2019. Poster P1068.
2. Kumar J, Tencer T, Swallow E, Patterson-Lomba O, Carley C, Signorovitch J. Number-needed-to-treat analysis and risk-benefit assessment of ozanimod compared with first-line disease-modifying therapies for relapsing-remitting multiple sclerosis. Presented at: ECTRIMS 2019, Stockholm, Sweden; September 11-13, 2019. Poster EP1590.
Trastuzumab Biosimilar Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers
December 5th 2023EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union (EU) for the treatment of patients with HER2-positive (HER2+) breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the European Union.
Read More
Data From Phase 3 Trials Demonstrate Efficacy of Dupilumab for Treating COPD, Type 2 Inflammation
December 4th 2023Patients with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation had significantly better lung function at least a year into a dupilumab regimen.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
New Data Update Myasthenia Gravis Outcomes for Patients in Australia
December 3rd 2023Patients living with myasthenia gravis in Australia were surveyed their demographic information, clinical features of the autoimmune disease, adverse effects from treatment, and quality of life. Outcomes were compared against 2011 data from Australia and 2019 data from the United States.
Read More
NK Cell Therapy SNK01 Improves Cognitive Function in Alzheimer Disease for up to 11 Weeks
December 3rd 2023Among 10 patients evaluated, compared with their baseline at 1 week after receiving their final dose in the trial, 30% demonstrated clinical improvement on the Alzheimer’s disease composite score.
Read More